RGNX Earnings

RGNX reported its FY2025Q3 earnings on 2025-11-06, showcasing a revenue of 30.00M against an estimate of 24.00M, resulting in a 21.83% surprise. The EPS was -1.2, surpassing the expected -1.38 by 13.04% . The stock experienced a -3.79% price change on the earnings day and a -0.52% change over the next five days, reflecting market reactions to the results.

Following RGNX's FY2025Q3 earnings announcement on 2025-11-06, the stock price moved by -3.79% on the day of the release. Over the subsequent five days, it saw a -0.52% change. Historically, RGNX's stock price tends to shift by an average of +0.97% in the 10 days leading up to earnings and +3.79% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate RGNX’s annual revenue to reach 62.00M, while the EPS is projected at -1.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -13.96% and EPS estimates Revise Downward by -29.87% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between RGNX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -13.96%, while EPS estimates moved Revise Downward by -29.87% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, RGNX's stock price typically moves by +0.97% in the 10 days before its earnings and +3.79% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -1.00 and revenue of 62.00M.

The earnings call highlights strong financial performance with a 25% YoY revenue increase and a solid cash position. The strategic partnerships with Nippon Shinyaku and AbbVie, along with optimistic guidance, contribute positively. The Q&A session reveals confidence in regulatory pathways and manufacturing capabilities, despite some uncertainty in pricing and Medicare coverage details. Overall, the company's financial health, strategic partnerships, and optimistic guidance suggest a positive stock price reaction.